The historical rank and industry rank for Nabriva Therapeutics's Gross Margin % or its related term are showing as below:
NBRVF's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.94 * Ranked among companies with meaningful Gross Margin % only.
Nabriva Therapeutics had a gross margin of -252.53% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Nabriva Therapeutics was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Nabriva Therapeutics had a gross margin of -252.53% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Nabriva Therapeutics Gross Margin % Related Terms
Nabriva Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Nabriva Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NBRVF vs BXRX, INM, ADTX: Gross Margin % Comparison
For the Biotechnology subindustry, Nabriva Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nabriva Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Nabriva Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Nabriva Therapeutics (NBRVF) has a Gross Margin % of -252.53% as of Jun. 2023. Gross margin is the ratio of total gross profit to net sales. View historical data on Nabriva Therapeutics and its competitors.
Is Nabriva Therapeutics' Gross Margin % too high?
Nabriva Therapeutics' current Gross Margin % is -252.53%. Overall, Nabriva Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nabriva Therapeutics' Gross Margin % compare to BXRX and INM?
Nabriva Therapeutics' Gross Margin % of -252.53% can be compared against companies in the Biotechnology industry. The industry median Gross Margin % is 60.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Nabriva Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nabriva Therapeutics's current Gross Margin % is -252.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nabriva Therapeutics stock overvalued right now?
Nabriva Therapeutics (NBRVF) has a current Gross Margin % of -252.53%. The current Gross Margin % is -252.53%. Nabriva Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Nabriva Therapeutics (NBRVF), the current Gross Margin % is -252.53% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. The company is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
12GF Score
Get the complete analysis for NBRVF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NBRVF has been successfully added to your 
